For research use only. Not for therapeutic Use.
Eliglukast tartrate（Cat No.:I005521） is a medication used as an inhibitor of glucosylceramide synthetase, specifically targeting the hepatic drug-metabolizing enzyme cytochrome P450 2D6 (CYP2D6). It is primarily employed for the long-term treatment of adults diagnosed with type 1 Gaucher disease, a rare genetic disorder characterized by the deficiency of glucocerebrosidase enzyme activity. By inhibiting glucosylceramide synthetase, eliglustat tartrate helps reduce the accumulation of glucosylceramide in cells, aiding in the management of Gaucher disease. It plays a crucial role in the maintenance and improvement of symptoms associated with this condition.
| Catalog Number | I005521 |
| CAS Number | 928659-70-5 |
| Synonyms | Genz-112638 |
| Molecular Formula | C23H36N2O4 • 1/2C4H6O6 |
| Purity | ≥95% |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IUPAC Name | N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid |
| InChI | InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1 |
| InChIKey | KUBARPMUNHKBIQ-VTHUDJRQSA-N |
| SMILES | CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O |
| Reference | [1]. Lukina E, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010 Aug 12;116(6):893-9. |
